Skip to main content

Table 1 Demographic characteristics and disease severities of ICU patients with nosocomial pneumonia treated with and without nebulized colistin in substitutive strategya

From: Role of nebulized colistin as a substitutive strategy against nosocomial pneumonia caused by CR-GNB in intensive care units: a retrospective cohort study

 

All cases

Substitutive nebulized colistin

p value

Yes

No

Case number

557

343

214

 

Mean age (SD)

72.7 (16.0)

74.1 (15.6)

69.3 (16.3)

< 0.001

Male

391 (70.2%)

238 (69.4%)

153 (71.5%)

0.597

Mean BMI (SD)

23.0 (4.6)

23.0 (5.0)

23.1 (4.1)

0.670

Smoking history

172 (30.9%)

81 (23.6%)

91 (42.5%)

< 0.001

Isolated pathogens

   

< 0.001

 CRAB

454 (81.5%)

304 (88.6%)

150 (70.1%)

 

 CRE

48 (8.6%)

25 (7.3%)

23 (10.7%)

 

 CR-Pseudomonas

55 (9.9%)

14 (4.1%)

41 (19.2%)

 

Pneumonia types

   

0.736

 HAP

395 (70.9%)

245 (71.4%)

150 (70.1%)

 

 VAP

162 (29.1%)

98 (28.6%)

64 (29.9%)

 

ICU types

   

< 0.001

 Medical ICU

308 (55.3%)

213 (62.1%)

95 (44.4%)

 

 Surgical ICU

249 (44.7%)

130 (37.9%)

119 (55.6%)

 

Comorbidities

    

 Malignancies

112 (20.1%)

78 (22.7%)

34 (15.9%)

0.050

 Renal insufficiency

126 (22.6%)

103 (30.0%)

23 (10.7%)

< 0.001

 Chronic lung diseasesb

109 (19.6%)

75 (21.9%)

34 (15.9%)

0.084

 Diabetes

192 (34.5%)

130 (37.9%)

62 (29.0%)

0.031

 Autoimmune disease

22 (3.9%)

19 (5.5%)

3 (1.4%)

0.015

Intravenous antibiotics

 Sulbactam

196 (35.2%)

136 (39.7%)

60 (28.0%)

0.005

 Carbapenem

276 (49.6%)

135 (39.4%)

141 (65.9%)

< 0.001

 Tigecycline

156 (28.0%)

110 (32.1%)

46 (21.5%)

0.007

 Inappropriate empiric therapy

429 (77.0%)

260 (75.8%)

169 (79.0%)

0.387

 APACHE II scores (Median, IQR)

20 (16–24)

20 (16–23)

22 (17–25)

< 0.001

 SOFA scores (Median, IQR)

7 (5–9)

7 (5–9)

7 (4.8–9)

0.802

Presenting featuresc

 Septic shock

73 (13.1%)

48 (14.0%)

25 (11.7%)

0.432

 Invasive ventilator

475 (85.3%)

281 (81.9%)

194 (90.7%)

0.005

 PF ratio < 200

119 (21.4%)

74 (21.6%)

45 (21%)

0.878

 Dialysisd

76 (13.6%)

61 (17.8%)

15 (7.0%)

< 0.001

Laboratory results (Median, IQR)

 Leukocytes (× 109 per L)

10,900 (7685–15,100)

10,700 (7700–14,700)

11,265 (7637–16,057)

0.203

 Albumin (g/dL)

3.0 (2.6–3.3)

3.1 (2.7–3.3)

2.8 (2.4–3.2)

< 0.001

 CRP (mg/dL)

7.8 (3.3–12.4)

7.4 (3.2–11.4)

8.6 (3.9–13.7)

0.029

Nebulized colistin (Median, IQR)

 Dosage (MIU in CMS)

–

6 (4–15)

–

 

 Treatment duration (days)

 

7 (6–11)

–

 
  1. APACHE II, Acute Physiology and Chronic Health Evaluation II; BMI, body mass index; CR-Pseudomonas, carbapenem-resistant Pseudomonas aeruginosa; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; HAP, hospital acquired pneumonia; ICU, intensive care unit; IQR, interquartile range; PF ratio, PaO2/FiO2 ratio; SD, standard deviation; SOFA, Sequential Organ Failure Assessment; VAP, ventilator-associated pneumonia
  2. aData are presented as n (%)
  3. bIncluding COPD, asthma, bronchiectasis, and pulmonary fibrosis
  4. cPresence of organ dysfunction on pneumonia index date
  5. dIncluding hemodialysis and continuous venovenous hemofiltration